These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 17508773)
41. The discovery of potential acetylcholinesterase inhibitors: a combination of pharmacophore modeling, virtual screening, and molecular docking studies. Lu SH; Wu JW; Liu HL; Zhao JH; Liu KT; Chuang CK; Lin HY; Tsai WB; Ho Y J Biomed Sci; 2011 Jan; 18(1):8. PubMed ID: 21251245 [TBL] [Abstract][Full Text] [Related]
43. Investigating the disease-modifying properties of sclerotiorin in Alzheimer's therapy using acetylcholinesterase inhibition. Ayyolath A; Kallingal A; Kundil VT; Suresh AM; Jayadevi Variyar E Chem Biol Drug Des; 2023 Aug; 102(2):292-302. PubMed ID: 37076430 [TBL] [Abstract][Full Text] [Related]
44. Toxicological and pharmacological evaluation, antioxidant, ADMET and molecular modeling of selected racemic chromenotacrines {11-amino-12-aryl-8,9,10,12-tetrahydro-7H-chromeno[2,3-b]quinolin-3-ols} for the potential prevention and treatment of Alzheimer's disease. Oset-Gasque MJ; González MP; Pérez-Peña J; García-Font N; Romero A; del Pino J; Ramos E; Hadjipavlou-Litina D; Soriano E; Chioua M; Samadi A; Raghuvanshi DS; Singh KN; Marco-Contelles J Eur J Med Chem; 2014 Mar; 74():491-501. PubMed ID: 24502897 [TBL] [Abstract][Full Text] [Related]
45. Docking of the alkaloid geissospermine into acetylcholinesterase: a natural scaffold targeting the treatment of Alzheimer's disease. Araújo JQ; Lima JA; Pinto Ada C; de Alencastro RB; Albuquerque MG J Mol Model; 2011 Jun; 17(6):1401-12. PubMed ID: 20844909 [TBL] [Abstract][Full Text] [Related]
46. A combinatorial approach to screen structurally diverse acetylcholinesterase inhibitory plant secondary metabolites targeting Alzheimer's disease. Choudhir G; Sharma S; Hariprasad P J Biomol Struct Dyn; 2022; 40(22):11705-11718. PubMed ID: 34351840 [TBL] [Abstract][Full Text] [Related]
47. Identification of New Potent Acetylcholinesterase Inhibitors Using Virtual Screening and in vitro Approaches. Mokrani EH; Bensegueni A; Chaput L; Beauvineau C; Djeghim H; Mouawad L Mol Inform; 2019 May; 38(5):e1800118. PubMed ID: 30725535 [TBL] [Abstract][Full Text] [Related]
48. Development of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease. Taylor P Neurology; 1998 Jul; 51(1 Suppl 1):S30-5; discussion S65-7. PubMed ID: 9674760 [TBL] [Abstract][Full Text] [Related]
49. Acetylcholinesterase inhibitors as a starting point towards improved Alzheimer's disease therapeutics. Recanatini M; Valenti P Curr Pharm Des; 2004; 10(25):3157-66. PubMed ID: 15544505 [TBL] [Abstract][Full Text] [Related]
50. Contemporary anticholinesterase pharmaceuticals of natural origin and their synthetic analogues for the treatment of Alzheimer's disease. Orhan G; Orhan I; Subutay-Oztekin N; Ak F; Sener B Recent Pat CNS Drug Discov; 2009 Jan; 4(1):43-51. PubMed ID: 19149713 [TBL] [Abstract][Full Text] [Related]
51. Marine natural products as acetylcholinesterase inhibitor: comparative quantum mechanics and molecular docking study. Farrokhnia M; Nabipour I Curr Comput Aided Drug Des; 2014 Mar; 10(1):83-95. PubMed ID: 24712383 [TBL] [Abstract][Full Text] [Related]
52. Discovery of new acetylcholinesterase inhibitors with small core structures through shape-based virtual screening. Chen Y; Liu ZL; Fu TM; Li W; Xu XL; Sun HP Bioorg Med Chem Lett; 2015 Sep; 25(17):3442-6. PubMed ID: 26212777 [TBL] [Abstract][Full Text] [Related]
53. Discovery of anti-Alzheimer agents: current ligand-based approaches toward the design of acetylcholinesterase inhibitors. Speck-Planche A; Luan F; Cordeiro MN Mini Rev Med Chem; 2012 Jun; 12(6):583-91. PubMed ID: 22587771 [TBL] [Abstract][Full Text] [Related]
54. Computational pharmaceutical analysis of anti-Alzheimer's Chinese medicine Coptidis Rhizoma alkaloids. Hong HJ; Chen PY; Shih TC; Ou CY; Jhuo MD; Huang YY; Cheng CH; Wu YC; Chung JG Mol Med Rep; 2012 Jan; 5(1):142-7. PubMed ID: 22002431 [TBL] [Abstract][Full Text] [Related]
55. Acetylcholinesterase inhibitors for the treatment of dementia in Alzheimer's disease: do we need new inhibitors? Small DH Expert Opin Emerg Drugs; 2005 Nov; 10(4):817-25. PubMed ID: 16262564 [TBL] [Abstract][Full Text] [Related]
57. The exploration of novel Alzheimer's therapeutic agents from the pool of FDA approved medicines using drug repositioning, enzyme inhibition and kinetic mechanism approaches. Hassan M; Raza H; Abbasi MA; Moustafa AA; Seo SY Biomed Pharmacother; 2019 Jan; 109():2513-2526. PubMed ID: 30551512 [TBL] [Abstract][Full Text] [Related]
58. From traditional European medicine to discovery of new drug candidates for the treatment of dementia and Alzheimer's disease: acetylcholinesterase inhibitors. Russo P; Frustaci A; Del Bufalo A; Fini M; Cesario A Curr Med Chem; 2013; 20(8):976-83. PubMed ID: 23210783 [TBL] [Abstract][Full Text] [Related]
59. Virtual screening, ADMET profiling, molecular docking and dynamics approaches to search for potent selective natural molecules based inhibitors against metallothionein-III to study Alzheimer's disease. Roy S; Kumar A; Baig MH; Masařík M; Provazník I Methods; 2015 Jul; 83():105-10. PubMed ID: 25920949 [TBL] [Abstract][Full Text] [Related]
60. A Novel Application of Multiscale Entropy in Electroencephalography to Predict the Efficacy of Acetylcholinesterase Inhibitor in Alzheimer's Disease. Tsai PH; Chang SC; Liu FC; Tsao J; Wang YH; Lo MT Comput Math Methods Med; 2015; 2015():953868. PubMed ID: 26120358 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]